Zai Lab (ZLAB) Projected to Announce Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Zai Lab to post earnings of ($0.6794) per share and revenue of $103.8660 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $99.61 million for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%. On average, analysts expect Zai Lab to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Down 0.5%

Zai Lab stock opened at $18.18 on Tuesday. Zai Lab has a 52-week low of $15.96 and a 52-week high of $39.64. The firm has a market cap of $2.07 billion, a PE ratio of -11.22 and a beta of 0.78. The company’s 50 day moving average is $18.59 and its two-hundred day moving average is $19.22.

Insider Transactions at Zai Lab

In other Zai Lab news, CFO Yajing Chen sold 2,264 shares of Zai Lab stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $17.46, for a total transaction of $39,529.44. Following the transaction, the chief financial officer owned 35,691 shares of the company’s stock, valued at $623,164.86. The trade was a 5.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William Lis sold 7,040 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $18.09, for a total value of $127,353.60. Following the completion of the sale, the director directly owned 50,437 shares of the company’s stock, valued at $912,405.33. The trade was a 12.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 90,873 shares of company stock worth $1,730,096. Corporate insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

A hedge fund recently raised its position in Zai Lab stock. Royal Bank of Canada increased its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZLAB has been the topic of a number of recent research reports. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Finally, Citigroup cut their price target on Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zai Lab presently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.